Loughborough University
Browse
Wilson_Shariatzadeh2020_Article_DistributedAutomatedManufactur.pdf (3.4 MB)

Distributed automated manufacturing of pluripotent stem cell products

Download (3.4 MB)
journal contribution
posted on 2019-12-05, 11:02 authored by Maryam Shariatzadeh, Amit Chandra, Sammy WilsonSammy Wilson, Mark McCall, Lise Morizur, Léa Lesueur, Olivier Chose, Michael M Gepp, André Schulz, Julia C Neubauer, Heiko Zimmermann, Elsa Abranches, Jennifer Man, Orla O’Shea, Glyn Stacey, Zoe Hewitt, David Williams
Establishing how to effectively manufacture cell therapies is an industry-level problem. Decentralised manufacturing is of increasing importance, and its challenges are recognised by healthcare regulators with deviations and comparability issues receiving specific attention from them. This paper is the first to report the deviations and other risks encountered when implementing the expansion of human pluripotent stem cells (hPSCs) in an automated three international site–decentralised manufacturing setting. An experimental demonstrator project expanded a human embryonal carcinoma cell line (2102Ep) at three development sites in France, Germany and the UK using the CompacT SelecT (Sartorius Stedim, Royston, UK) automated cell culture platform. Anticipated variations between sites spanned material input, features of the process itself and production system details including different quality management systems and personnel. Where possible, these were pre-addressed by implementing strategies including standardisation, cell bank mycoplasma testing and specific engineering and process improvements. However, despite such measures, unexpected deviations occurred between sites including software incompatibility and machine/process errors together with uncharacteristic contaminations. Many only became apparent during process proving or during the process run. Further, parameters including growth rate and viability discrepancies could only be determined post-run, preventing ‘live’ corrective measures. The work confirms the critical nature of approaches usually taken in Good Manufacturing Practice (GMP) manufacturing settings and especially emphasises the requirement for monitoring steps to be included within the production system. Real-time process monitoring coupled with carefully structured quality systems is essential for multiple site working including clarity of decision-making roles. Additionally, an over-reliance upon post-process visual microscopic comparisons has major limitations; it is difficult for non-experts to detect deleterious culture changes and such detection is slow.

Funding

UK Regenerative Medicine Platform (UK-RMP) Pluripotent Stem Cell Platform (funder reference MR/L012537/1) and its extension (MRC) Cross Border Starting Material Compatibility Study Using Single Process Engineering Team

History

School

  • Mechanical, Electrical and Manufacturing Engineering

Published in

The International Journal of Advanced Manufacturing Technology

Volume

106

Pages

1085–1103

Publisher

Springer Science and Business Media LLC

Version

  • VoR (Version of Record)

Rights holder

© The Authors

Publisher statement

This is an Open Access Article. It is published by Springer under the Creative Commons Attribution 4.0 Unported Licence (CC BY). Full details of this licence are available at: http://creativecommons.org/licenses/by/4.0/

Acceptance date

2019-09-27

Publication date

2019-12-04

Copyright date

2020

ISSN

0268-3768

eISSN

1433-3015

Language

  • en

Depositor

Dr Sammy Wilson Deposit date: 5 December 2019

Usage metrics

    Loughborough Publications

    Categories

    No categories selected

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC